Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies

References

• Andreeff M, Goodrich D, Koeffler HP. Cell Proliferation and Differentiation. In: Hong WK, Bast RC, Hait WN, Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. Shelton, Connecticut: People's Medical Publishing House; 2010. p. 26-39.
   Google Scholar
• Balmer CM, Valley AW, Iannucci A. Cancer Treatment and Chemotherapy. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: A Pathophysiologic Approach. 6th ed. New York: McGraw-Hill; 1999. p. 2279-38.
   Google Scholar
• Johnson N, Shapiro GI. Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. Expert Opin Ther Targets. 2010; 14(11):1199-212; PMID:20932174; http://dx.doi.org/10.1517/14728222.2010.525221
   PubMed Web of Science ®Google Scholar
• Cicenas J, Valius M. The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol 2011; 137(10):1409-18; PMID:21877198; http://dx.doi.org/10.1007/s00432-011-1039-4
   PubMed Web of Science ®Google Scholar
• Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010; 9(10):790-803; PMID:20885410; http://dx.doi.org/10.1038/nrd3253
   PubMed Web of Science ®Google Scholar
• Perry CM. Eribulin. Drugs 2011; 71(10):1321-31; PMID:21770478; http://dx.doi.org/10.2165/11207520-000000000-00000
   PubMed Web of Science ®Google Scholar
• Janus A, Robak T, Smolewski P. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett 2005; 10(3):479-98; PMID:16217558
   PubMed Web of Science ®Google Scholar
• Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4(5):335-48; PMID:15122205; http://dx.doi.org/10.1038/nrc1362
   PubMed Web of Science ®Google Scholar
• Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol 2005; 23(23):5386-403; PMID:15983388; http://dx.doi.org/10.1200/JCO.2005.23.648
   PubMed Web of Science ®Google Scholar
• Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001; 70: 369-413; PMID:11395412; http://dx.doi.org/10.1146/annurev.biochem.70.1.369
   PubMed Web of Science ®Google Scholar
• Dennis MJ, Beijnen JH, Grochow LB, van Warmerdam LJ. An overview of the clinical pharmacology of topotecan. Semin Oncol 1997; 24(1 Suppl 5):S5-12-S5-8; PMID:9122737
   PubMed Web of Science ®Google Scholar
• Stewart CF. Topoisomerase I interactive agents. Cancer Chemother Biol Response Modif 2001; 19: 85-128; PMID:11686040
   PubMedGoogle Scholar
• Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008; 14(6):1649-57; PMID:18347166; http://dx.doi.org/10.1158/1078-0432.CCR-07-2218
   PubMed Web of Science ®Google Scholar
• Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59(11):2615-22; PMID:10363983
   PubMed Web of Science ®Google Scholar
• Chesnel F, Bazile F, Pascal A, Kubiak JZ. Cyclin B dissociation from CDK1 precedes its degradation upon MPF inactivation in mitotic extracts of Xenopus laevis embryos. Cell Cycle 2006; 5(15):1687-98; PMID:16921258; http://dx.doi.org/10.4161/cc.5.15.3123
   PubMed Web of Science ®Google Scholar
• Geoerger B, Kerr K, Tang CB, Fung KM, Powell B, Sutton LN, Phillips PC, Janss AJ. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 2001; 61(4):1527-32; PMID:11245461
   PubMed Web of Science ®Google Scholar
• Kidd M, Eick G R P, Murren J, Culler M, Modlin IM. Effect of pan-inhibitory somatostatin analogues, topotecan and bortezomib on the human enterochromaffin neoplastic cell line KRJ-I. J Clin Oncol (Meeting Abstracts). 2006; 24(13144)
   Google Scholar
• Leleu X, O'Sullivan G, Jia X, Ngo H, Moreau AS, Roccaro A, et al. The combination of the mTOR inhibitor rapamycin and proteasome inhibitor bortezomib is synergistic in vitro in multiple myeloma Haematologica. 2007; 92([suppl. 2: abstr PO-534)
   Google Scholar
• Morgan R, Valdes-Albini F, Synold T, Somlo G, Shibata S, Chow WA, et al. Phase I trial of bortezomib in combination with topotecan in advanced solid tumor malignancies. J Clin Oncol (Meeting Abstracts). 2006; 24(12004)
   PubMed Web of Science ®Google Scholar
• Nagourney R, Su Y, Horlick D, Chow C, Kollin C, Evans S. Bortezomib (PS-341) alone and in combination with cytotoxic drugs: Ex vivo analysis in human tumor primary cultures. AACR Meeting Abstracts 2004; (851-a)
   Google Scholar
• Boni J, Leister C, Burns J, Cincotta M, Hug B, Moore L. Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications. J Clin Pharmacol 2007; 47(11):1430-9; PMID:17913896; http://dx.doi.org/10.1177/0091270007306957
   PubMed Web of Science ®Google Scholar
• Chappell MJ, Evans ND, Errington RJ, Khan IA, Campbell L, Ali R, Godfrey KR, Smith PJ. A coupled drug kinetics-cell cycle model to analyse the response of human cells to intervention by topotecan. Comput Methods Programs Biomed 2008; 89(2):169-78; PMID:18082908; http://dx.doi.org/10.1016/j.cmpb.2007.11.002
   PubMed Web of Science ®Google Scholar
• Cheung SY, Evans ND, Chappell MJ, Godfrey KR, Smith PJ, Errington RJ. Exploration of the intercellular heterogeneity of topotecan uptake into human breast cancer cells through compartmental modelling. Math Biosci 2008; 213(2):119-34; PMID:18482740; http://dx.doi.org/10.1016/j.mbs.2008.03.008
   PubMed Web of Science ®Google Scholar
• Kohn KW. Molecular interaction map of the mammalian cell cycle control and DNA repair systems. Mol Biol Cell 1999; 10(8):2703-34; PMID:10436023; http://dx.doi.org/10.1091/mbc.10.8.2703
   PubMed Web of Science ®Google Scholar
• Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff D, Conrad C, Fink KL, Robins HI, Mehta M, et al. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res 2007; 13(24):7401-6; PMID:18094423; http://dx.doi.org/10.1158/1078-0432.CCR-07-0781
   PubMed Web of Science ®Google Scholar
• Leveque D, Carvalho MC, Maloisel F. Review. Clinical pharmacokinetics of bortezomib. In Vivo 2007; 21(2):273-8; PMID:17436576
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Tobinai K, Ogura M, Ando K, Tsuchiya T, Kobayashi Y, Watanabe T, Maruyama D, Morishima Y, Kagami Y, et al. Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma. Cancer Sci. 2008; 99(1):140-4; PMID:17970782
   PubMed Web of Science ®Google Scholar
• Panetta JC, Schaiquevich P, Santana VM, Stewart CF. Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma. Clin Cancer Res 2008; 14(1):318-25; PMID:18172284; http://dx.doi.org/10.1158/1078-0432.CCR-07-1243
   PubMed Web of Science ®Google Scholar
• Punt CJ, Boni J, Bruntsch U, Peters M, Thielert C. Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 2003; 14(6):931-7; PMID:12796032; http://dx.doi.org/10.1093/annonc/mdg248
   PubMed Web of Science ®Google Scholar
• Jiang H, Fine JP. Survival analysis. Methods Mol Biol 2007; 404: 303-18; PMID:18450056; http://dx.doi.org/10.1007/978-1-59745-530-5_15
   PubMedGoogle Scholar
• Chang SF, Chang CA, Lee DY, Lee PL, Yeh YM, Yeh CR, Cheng CK, Chien S, Chiu JJ. Tumor cell cycle arrest induced by shear stress: Roles of integrins and Smad. Proc Natl Acad Sci U S A 2008; 105(10):3927-32; PMID:18310319; http://dx.doi.org/10.1073/pnas.0712353105
   PubMed Web of Science ®Google Scholar
• Kiino DR, Burger DE, Dannies PS. Prolactin storage in a clonal strain of rat pituitary tumor cells is cell-cycle dependent. J Cell Biol 1982; 93(2):459-62; PMID:7047539; http://dx.doi.org/10.1083/jcb.93.2.459
   PubMed Web of Science ®Google Scholar
• Wall SJ, Werner E, Werb Z, DeClerck YA. Discoidin domain receptor 2 mediates tumor cell cycle arrest induced by fibrillar collagen. J Biol Chem 2005; 280(48):40187-94; PMID:16186104; http://dx.doi.org/10.1074/jbc.M508226200
   PubMed Web of Science ®Google Scholar
• Zhu X, Kumar R, Mandal M, Sharma N, Sharma HW, Dhingra U, Sokoloski JA, Hsiao R, Narayanan R. Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc Natl Acad Sci U S A 1996; 93(12):6091-5; PMID:8650224; http://dx.doi.org/10.1073/pnas.93.12.6091
   PubMed Web of Science ®Google Scholar
• Li YY, Chang JW, Chou WC, Liaw CC, Wang HM, Huang JS, Wang CH, Yeh KY. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer 2008; 59(2):180-91; PMID:17900752; http://dx.doi.org/10.1016/j.lungcan.2007.08.026
   PubMed Web of Science ®Google Scholar
• Li DM, Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci U S A 1998; 95(26):15406-11; PMID:9860981; http://dx.doi.org/10.1073/pnas.95.26.15406
   PubMed Web of Science ®Google Scholar
• Ferguson PJ, Kurowska E, Freeman DJ, Chambers AF, Koropatnick DJ. A flavonoid fraction from cranberry extract inhibits proliferation of human tumor cell lines. J Nutr 2004; 134(6):1529-35; PMID:15173424
   PubMed Web of Science ®Google Scholar
• Blajeski AL, Phan VA, Kottke TJ, Kaufmann SH. G(1) and G(2) cell-cycle arrest following microtubule depolymerization in human breast cancer cells. J Clin Invest 2002; 110(1):91-9; PMID:12093892; http://dx.doi.org/10.1172/JCI13275
   PubMed Web of Science ®Google Scholar
• Tsujioka T, Tochigi A, Kishimoto M, Kondo T, Tasaka T, Wada H, Sugihara T, Yoshida Y, Tohyama K. DNA ploidy and cell cycle analyses in the bone marrow cells of patients with megaloblastic anemia using laser scanning cytometry. Cytometry B Clin Cytom 2008; 74(2):104-9; PMID:18044723; http://dx.doi.org/10.1002/cyto.b.20389
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Kantarjian HM. The hyper-CVAD regimen in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am 2000; 14(6):1381-96, x-xi; PMID:11147229; http://dx.doi.org/10.1016/S0889-8588(05)70192-1
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3):205-16; PMID:10655437; http://dx.doi.org/10.1093/jnci/92.3.205
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17(4):1244
   PubMed Web of Science ®Google Scholar
• Panetta JC. A mathematical model of breast and ovarian cancer treated with paclitaxel. Mathematical Biosciences 1997; 146(2):89-113; PMID:9348741; http://dx.doi.org/10.1016/S0025-5564(97)00077-1
   PubMed Web of Science ®Google Scholar